Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and ...

Panelists discuss how axatilimab emerges as a promising later-line treatment option for patients with refractory or recurrent ...

Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease ...

Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

The novel agent LP-184 has been granted rare pediatric disease designations in malignant rhabdoid tumors, rhabdomyosarcoma, ...

A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line ...

During a Case-Based Roundtable® event,  Michael R. Bishop, MD, moderated a discussion on monitoring and treatment of chronic ...

Nancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival ...